Non-insulin-dependent diabetes mellitus (NIDDM) is a major health problem affecting approximately 14 million Americans. It causes significant morbidity and mortality and imposes a great economic burden as the annual cost of diabetes currently exceeds $20 billion. Moreover, the socioeconomic effects of NIDDM are expected to escalate with the increase in its prevalence due to aging of the American society and rapid growth of minority populations at high risk for the disease. Since most of the morbidity and mortality of NIDDM arise from its long-term complication, prevention and early detection of the disease should have a tremendous human, social, and economic impact. The major aim of this proposal is to test the hypothesis that intervention can prevent or delay the decompensation from impaired glucose tolerance (IGT) to NIDDM and the progression to fasting hyperglycemia in normoglycemic newly diagnosed NIDDM and possibly reduce the incidence of atherosclerotic cardiovascular (ASCVD). As part of the multicenter NIDDM primary prevention trial (DK- 93-07), we plan to study 200 obese (body mass index greater than or equal to 27kg/m2) subjects (100 whites, and 100 blacks) aged 40-65 years with persistent IGT or newly diagnosed NIDDM (with fasting normoglycemia) according to the World Health Organization criteria. They will be recruited from the population of Los Angeles served by Southern California Kaiser Permanente Foundation on the basis of fasting plasma glucose concentration measured during their routine health care. The proposed intervention is a 2x2 factorial design with one factor being a special low-fat diet and exercise program versus usual care and the second factor being a drug that improves insulin sensitivity (e.g., the biguanide metformin) versus placebo. The primary endpoints will be the development of NIDDM for subjects with IGT and worsening to fasting hyperglycemia for those with newly diagnosed NIDDM. The secondary endpoints will be changes in blood pressure, the concentrations of lipids, lipoproteins, fibrinogen, ad plasminogen activator inhibitor 1, and the development of ASCVD as assessed from the clinical data, the ankle/arm ratio, and the electrocardiogram. The success of this trial will have a great impact in alleviating human suffering and decreasing the socioeconomic effects of NIDDM.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK048443-04S1
Application #
2834884
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Garfield, Sanford A
Project Start
1994-08-20
Project End
2001-06-30
Budget Start
1997-09-22
Budget End
1998-06-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
de Groot, Mary; Marrero, David; Mele, Lisa et al. (2018) Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. Psychosom Med 80:167-173
Kim, Catherine; Aroda, Vanita R; Goldberg, Ronald B et al. (2018) Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab 103:486-496
Fujiyoshi, Akira; Jacobs Jr, David R; Alonso, Alvaro et al. (2017) Validity of Death Certificate and Hospital Discharge ICD Codes for Dementia Diagnosis: The Multi-Ethnic Study of Atherosclerosis. Alzheimer Dis Assoc Disord 31:168-172
Baek, Jonggyu; Hirsch, Jana A; Moore, Kari et al. (2017) Statistical Methods to Study Variation in Associations Between Food Store Availability and Body Mass in the Multi-Ethnic Study of Atherosclerosis. Epidemiology 28:403-411
Rockette-Wagner, Bonny; Storti, Kristi L; Dabelea, Dana et al. (2017) Activity and Sedentary Time 10 Years After a Successful Lifestyle Intervention: The Diabetes Prevention Program. Am J Prev Med 52:292-299
Crandall, Jill P; Mather, Kieren; Rajpathak, Swapnil N et al. (2017) Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 5:e000438
Luchsinger, José A; Ma, Yong; Christophi, Costas A et al. (2017) Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care 40:958-965
Goldberg, Ronald B; Aroda, Vanita R; Bluemke, David A et al. (2017) Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation 136:52-64
Vella, Chantal A; Allison, Matthew A; Cushman, Mary et al. (2017) Physical Activity and Adiposity-related Inflammation: The MESA. Med Sci Sports Exerc 49:915-921
Sylvetsky, Allison C; Edelstein, Sharon L; Walford, Geoffrey et al. (2017) A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes. J Nutr 147:2060-2066

Showing the most recent 10 out of 37 publications